Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials
Ongoing Monitoring Weekly check-ins, regular blood work, treatment adjustments, and continuous support for sustainable results
Value Beyond Cost Consider the return on investment including improved health and wellness, enhanced performance and recovery, better quality of life, potentially reduced other healthcare costs, and prevention of age-related decline
The choice to initiate TRT and the mode of therapy should be made in consultation with a qualified and experienced healthcare provider, and based on an individuals hormone levels and signs and symptoms
It is found in virtually all body cells and acts as the body's own antioxidant
Fletcher MM, Belousoff MJ, Harikumar KG, et al
US$ 23.71
US$ 27.17
US$ 22.55
US$ 29.45
US$ 22.75
